HK1209740A1 - 二噁烯並-和噁嗪- 嘧啶 抑制劑化合物及使用方法 - Google Patents
二噁烯並-和噁嗪- 嘧啶 抑制劑化合物及使用方法Info
- Publication number
- HK1209740A1 HK1209740A1 HK15110598.8A HK15110598A HK1209740A1 HK 1209740 A1 HK1209740 A1 HK 1209740A1 HK 15110598 A HK15110598 A HK 15110598A HK 1209740 A1 HK1209740 A1 HK 1209740A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pi3k
- dioxino
- oxazin
- methods
- pyrimidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261694898P | 2012-08-30 | 2012-08-30 | |
PCT/EP2013/067861 WO2014033196A1 (en) | 2012-08-30 | 2013-08-29 | Dioxino- and oxazin-[2,3-d]pyrimidine pi3k inhibitor compounds and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1209740A1 true HK1209740A1 (zh) | 2016-04-08 |
Family
ID=49080882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15110598.8A HK1209740A1 (zh) | 2012-08-30 | 2015-10-28 | 二噁烯並-和噁嗪- 嘧啶 抑制劑化合物及使用方法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US9346817B2 (zh) |
EP (1) | EP2890698B1 (zh) |
JP (1) | JP6022691B2 (zh) |
KR (1) | KR101697444B1 (zh) |
CN (1) | CN104583215B (zh) |
BR (1) | BR112015002493A8 (zh) |
CA (1) | CA2879497C (zh) |
HK (1) | HK1209740A1 (zh) |
MX (1) | MX361157B (zh) |
RU (1) | RU2612251C2 (zh) |
WO (1) | WO2014033196A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2807785T3 (es) | 2014-10-22 | 2021-02-24 | Bristol Myers Squibb Co | Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k |
EP3209665B1 (en) | 2014-10-22 | 2019-08-14 | Bristol-Myers Squibb Company | Substituted pyrrolotriazine amine compounds as pi3k inhibitors |
EP3328866B1 (en) * | 2015-07-27 | 2019-10-30 | Eli Lilly and Company | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds and theit use as mutant idh1 inhibitors |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
US20200283444A1 (en) * | 2017-08-02 | 2020-09-10 | Northwestern University | Substituted fused pyrimidine compounds and uses thereof |
CN116981661A (zh) * | 2021-03-03 | 2023-10-31 | 劲方医药科技(上海)有限公司 | 稠环取代的六元杂环化合物及其制法和用途 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
US6274327B1 (en) | 1992-04-13 | 2001-08-14 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
US5846824A (en) | 1994-02-07 | 1998-12-08 | Ludwig Institute For Cancer Research | Polypeptides having kinase activity, their preparation and use |
GB9208135D0 (en) | 1992-04-13 | 1992-05-27 | Ludwig Inst Cancer Res | Polypeptides having kinase activity,their preparation and use |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
JPH08336393A (ja) | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法 |
US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
WO2003006151A1 (en) | 2001-07-12 | 2003-01-23 | Avecia Limited | Microencapsulated catalyst, methods of preparation and methods of use thereof |
GB0217294D0 (en) * | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicaments |
GB0311274D0 (en) * | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
CN104892582B (zh) | 2005-10-07 | 2019-09-27 | 埃克塞利希斯股份有限公司 | 作为用于治疗增生性疾病的mek抑制剂的吖丁啶 |
TW200808760A (en) | 2006-04-12 | 2008-02-16 | Basf Ag | 2-(pyridin-2-yl)pyrimidines as fungicides |
EP2402347A1 (en) * | 2006-04-26 | 2012-01-04 | F. Hoffmann-La Roche AG | Pharmaceutical compounds |
AR060632A1 (es) | 2006-04-26 | 2008-07-02 | Genentech Inc | Compuestos inhibidores de fosfoinositida 3- quinasa y metodos de uso |
UA97483C2 (ru) * | 2006-08-08 | 2012-02-27 | Чугай Сейяку Кабушики Кайша | Производное пиримидина в качестве ингибитора pi3k и его применение |
ZA200902382B (en) | 2006-10-19 | 2010-08-25 | Signal Pharm Llc | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors |
NZ578162A (en) | 2006-12-07 | 2011-12-22 | Genentech Inc | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
GB0721095D0 (en) * | 2007-10-26 | 2007-12-05 | Piramed Ltd | Pharmaceutical compounds |
WO2010027002A1 (ja) * | 2008-09-05 | 2010-03-11 | 塩野義製薬株式会社 | Pi3k阻害活性を有する縮環モルホリン誘導体 |
CN102480961A (zh) * | 2009-06-24 | 2012-05-30 | 健泰科生物技术公司 | 与含氧杂环稠合的嘧啶化合物、组合物和使用方法 |
RU2550821C2 (ru) | 2009-10-29 | 2015-05-20 | Сертрис Фармасьютикалз, Инк. | Бициклические пиридины и аналоги в качестве модуляторов сиртуина |
EP2558474B1 (en) * | 2010-04-13 | 2015-11-25 | Rigel Pharmaceuticals, Inc. | 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses |
SI2651951T1 (sl) * | 2010-12-16 | 2015-01-30 | F. Hoffmann-La Roche Ag | Tricikliäśne p13k inhibitorske spojine in postopki uporabe |
-
2013
- 2013-08-29 KR KR1020157005163A patent/KR101697444B1/ko active IP Right Grant
- 2013-08-29 JP JP2015529017A patent/JP6022691B2/ja active Active
- 2013-08-29 MX MX2015002501A patent/MX361157B/es active IP Right Grant
- 2013-08-29 CN CN201380044403.XA patent/CN104583215B/zh active Active
- 2013-08-29 CA CA2879497A patent/CA2879497C/en not_active Expired - Fee Related
- 2013-08-29 WO PCT/EP2013/067861 patent/WO2014033196A1/en active Application Filing
- 2013-08-29 RU RU2015108410A patent/RU2612251C2/ru not_active IP Right Cessation
- 2013-08-29 BR BR112015002493A patent/BR112015002493A8/pt not_active Application Discontinuation
- 2013-08-29 EP EP13753637.1A patent/EP2890698B1/en active Active
- 2013-08-29 US US14/013,256 patent/US9346817B2/en active Active
-
2015
- 2015-10-28 HK HK15110598.8A patent/HK1209740A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US9346817B2 (en) | 2016-05-24 |
US20140065136A1 (en) | 2014-03-06 |
KR20150038466A (ko) | 2015-04-08 |
MX361157B (es) | 2018-11-28 |
EP2890698B1 (en) | 2017-03-01 |
WO2014033196A1 (en) | 2014-03-06 |
EP2890698A1 (en) | 2015-07-08 |
RU2015108410A (ru) | 2016-10-20 |
JP6022691B2 (ja) | 2016-11-09 |
BR112015002493A2 (pt) | 2017-07-04 |
CN104583215B (zh) | 2016-12-07 |
JP2015526492A (ja) | 2015-09-10 |
BR112015002493A8 (pt) | 2019-07-30 |
CN104583215A (zh) | 2015-04-29 |
CA2879497C (en) | 2017-08-01 |
RU2612251C2 (ru) | 2017-03-03 |
MX2015002501A (es) | 2015-06-10 |
CA2879497A1 (en) | 2014-03-06 |
KR101697444B1 (ko) | 2017-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1215253A1 (zh) | 作為激酶抑制劑的吡咯並嘧啶化合物 | |
HK1204619A1 (zh) | 作為 抑制劑的新的 取代的氨基 -吡咯並 嘧啶類 | |
HK1200449A1 (zh) | 在治療過度增殖性疾病中用作 激酶抑制劑的取代的苄基吲唑 | |
IL235944A0 (en) | β-lactamase inhibitor compounds, preparations containing them, methods for their preparation and their uses | |
ZA201307839B (en) | Pyrazolo[4,3-d] pyrimidines useful as kinase inhibitors | |
LT3486245T (lt) | 2-amino-n-(piperidin-1-il-piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamidas, kaip atr kinazės inhibitorius | |
ZA201308062B (en) | Combinations of akt inhibitor compounds and erlotinib, and methods of use | |
EP2788000A4 (en) | PYRROLOPYRIMIDINES AS INHIBITORS OF KINASE JANUS | |
HK1209740A1 (zh) | 二噁烯並-和噁嗪- 嘧啶 抑制劑化合物及使用方法 | |
HK1211027A1 (zh) | 作為 抑制劑的吡咯並三嗪酮 | |
AP3849A (en) | Use of inhibitors of the activity or function of pi3k | |
HK1210771A1 (zh) | 氮雜吲哚衍生物 | |
HK1205106A1 (zh) | 取代的嘧啶化合物及其作為 抑制劑的用途 | |
ZA201407695B (en) | Triazolo compounds as pde 10 inhibitors | |
ZA201306416B (en) | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a) | |
HK1201066A1 (zh) | 端錨聚合酶的吡喃並吡啶酮抑制劑 | |
EP2844660A4 (en) | TRIAZOLOPYRIDAZIN COMPOUNDS, USE AS INHIBITORS OF KINASE-LRRK2 AND METHOD FOR THE PRODUCTION THEREOF | |
HK1211284A1 (zh) | 磷酸二酯酶 型的抑制劑化合物 | |
GB201209458D0 (en) | Novel compounds and their use as kinase inhibitors | |
GB201206048D0 (en) | Novel compounds and their use as kinase inhibitors | |
AU2012900650A0 (en) | Compounds and methods of their use | |
AU2012900651A0 (en) | Compounds and methods of their use |